Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.43 |
| ▸ | CYP11B1 | P15538 | 13/20 | 0.38 |
| ▸ | CYP11B2 | P19099 | 13/20 | 0.38 |
| ▸ | AR | P10275 | 4/20 | 0.38 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.35 |
| ▸ | ESR1 | P03372 | 1/20 | 0.35 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22023207 | 0.94 | TRPV4 (0.41) | TRPV4CYP11B1CYP11B2ARCACNA1H | |
| SCHEMBL24876709 | 0.80 | TRPV4 (0.46) | TRPV4CYP11B1CYP11B2AR | |
| SCHEMBL21099151 | 0.79 | ESR1 (0.41) | ARESR1ESR2 | |
| SCHEMBL495417 | 0.79 | TRPV4 (0.52) | TRPV4CYP11B1CYP11B2ARCACNA1H | |
| SCHEMBL23008623 | 0.78 | AR (0.39) | ARESR1ESR2 | |
| SCHEMBL26124467 | 0.78 | TRPV4 (0.50) | TRPV4CYP11B1CYP11B2AR | |
| SCHEMBL6474353 | 0.76 | AR (0.49) | TRPV4CYP11B1CYP11B2AR | |
| SCHEMBL22021976 | 0.75 | ESR1 (0.38) | ARESR1ESR2 | |
| SCHEMBL26394780 | 0.73 | TRPV4 (0.46) | TRPV4CYP11B1CYP11B2ARCACNA1H | |
| SCHEMBL495426 | 0.73 | CYP11B1 (0.57) | TRPV4CYP11B1CYP11B2AR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11078170-B2 | Cyclic sulfamide compounds and methods of using same | ASSEMBLY BIOSCIENCES, INC. (US) | 2021-08-03 | — | — | US | disclosed |
| US-20200157070-A1 | CYCLIC SULFAMIDE COMPOUNDS AND METHODS OF USING SAME | ASSEMBLY BIOSCIENCES INC (US) | 2020-05-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11078170-B2 | Cyclic sulfamide compounds and methods of using same | HCCS, HAVCR2, SLC10A1 | TRPV4 4698/4885CYP11B1 2155/4885CYP11B2 2106/4885 |
| US-20200157070-A1 | CYCLIC SULFAMIDE COMPOUNDS AND METHODS OF USING SAME | HCCS, HAVCR2, SLC10A1 | TRPV4 4698/4885CYP11B1 2155/4885CYP11B2 2106/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.